Almirall SA · BME:ALM
Almirall SA — Non-Deal Roadshow (October 2008)
46 slides from Almirall SA's roadshow presentation, October 2008
Slide 1: Almirall moving forward with aclidinium bromide
Almirall moving forward with aclidinium bromide Roadshow October 2008
Slide 2: Disclaimer
Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptio
Slide 3: Dr. Jorge Gallardo, Chairman and CEO
Dr. Jorge Gallardo Chairman and Chief Executive Officer 3
Slide 4: Almirall – Focus on growth and value creation
Almirall – Focus on growth and value creation Corporate vision Almirall aims to become a reference mid-cap R&D–driven pharma player by strengthening its Pan-European presence and expanding its global footprint through organic and non-organic growth In line to meet the guidance Total Net Sales of dou
Slide 5: Almirall – Solid fundamentals for innovation and growth
Almirall – Solid fundamentals for innovation and growth Value sources Strategic position Drivers for growth Capabilities / Opportunities #1 Spanish pharma, #3 in Broadest and deepest R&D capabilities in pipeline in company Respiratory, Autoinmune Spanish market. history. and Dermatology #1 d
Slide 6: Corporate Strategy
Almirall – Solid fundamentals for innovation and growth Corporate Strategy Corporate Strategy Strategic position Leveraging R&D LONG- Growing TERM Drivers for growth internationally VALUE Defending CREATION Spanish Leadership Opportunities / Capabilities 6
Slide 7: Almirall since IPO
Almirall since IPO Consistency and alignment with strategic goals Actual Estimate ’06 ’07 ‘08 Defend leadership position in Spain: In line with - Net sales 517,1 521,3 guidance - Headcount1 791 799 800 - Market share 5,7% 5,6% 5.5%2 International expansion: - Affiliates sales 161,0 186,4 In line
Slide 8: Almirall as investment case
Almirall as investment case Solid fundamentals focused on long term value creation Combining a well-established business … …with significant upside from pipeline Branded, patented balanced portfolio. Broadest and deepest pipeline in company history. Spanish leadership. Proven resilience to a
Slide 9: Mr. Luciano Conde, Chief Operating Officer
Mr. Luciano Conde Chief Operating Officer 9
Slide 10: Market companies and Spain are the growth drivers in 2008
Market companies and Spain are the growth drivers in 2008 2007 acquisitions driving international sales growth. On track to reach 2008 target. Net Sales Derma Sales to licensees in € million distribution/manufacturing Japan (Ebastine) and US agreements (Almotriptan) affected by 412.9 467.9 seasonali
Slide 11: Net Sales breakdown by Top Products
Net Sales breakdown by Top 10 Products YTD June YTD June % € thousand 2008 2007 Variation Ebastine 59.768 64.925 -7,9% Atorvastatine (Prevencor) 51.714 46.154 12,0% Salmeterol & Fluticasone (Plusvent) 31.517 33.308 -5,4% Aceclofenac (Airtal) 26.708 26.909 -0,7% Venlafaxine (Dobupal) 26.441 24.666 7,
Slide 12: Opportunities
Almirall has a track record of balancing issues with new opportunities 2005 2006 2007 2008 Moving forward Pantopan Hermal • Roll out of selected Hermal dermatology portfolio. license acquisition Opportunities for Italy • Launch of Solaraze and Vaniqa (new countries/new EU rights for Sativex presenta
Slide 13: Key take-aways from the base business
Key take-aways from the base business • Resilient branded, patented and well balanced product portfolio. • Current portfolio single digit top line sales evolution expected for 2009 and 2010 (excluding new Corporate Development projects). • Increased dermatology area presence in the company portfolio
Slide 14: Dr. Per Olof Andersson, Chief Scientific Officer
Dr. Per Olof Andersson Chief Scientific Officer 14
Slide 15: Proven R&D track record and competitive capabilities
Proven R&D track record and competitive capabilities A focused strategy that balances risk and reward International R&D capabilities with proven track record • R&D expense above 15% of sales. • 3 R&D centers in Spain and Germany with 600 staff. • 40 years of R&D tradition, 7 international products l
Slide 16: A transformational pipeline on track
Auto-immune A transformational pipeline on track Respiratory Dermatology Pipeline Status (the right end of each bar represents status of development as of Oct 15th) Expected filing Preclinical Ph I Ph II Ph III Registration date Aclidinium bromide (AB) (anti-muscarinic) COPD 4Q’09-1Q’10 (US) - 2011
Slide 17: ACCLAIM results
ACCLAIM results Aclidinium bromide shown to improve lung function and was well tolerated in the ACCLAIM (I &II) pivotal trials with a desirable risk/benefit profile • Consistent statistically significant improvements in FEV1 (trough and peak). • Health related quality of life benefit. • Increased ti
Slide 18: Aclidinium bromide Monotherapy - Regulatory Plans
Aclidinium bromide Monotherapy - Regulatory Plans US • Consultation with FDA in early 2009 to review ACCLAIM I & II trial results and discuss filing and development plans. • Forest plans to file with ACCLAIM data in 4Q 2009 or 1Q 2010, pending FDA feedback. EU • Regulatory interactions starting 4Q 2
Slide 19: Aclidinium bromide Monotherapy – Further Development Plans
Aclidinium bromide Monotherapy – Further Development Plans • Continue monotherapy development with higher QD doses and/or bid dosing. • The adverse event profile from the ACCLAIM studies suggests that higher doses will be well tolerated. • New studies to be initiated to evaluate different dosing reg
Slide 20: Aclidinium bromide – Combination Strategies
Aclidinium bromide – Combination Strategies Formoterol combination • The ACCLAIM results facilitate and potentially accelerate a strategy to develop a twice daily aclidinium/formoterol combination. • Phase II program to be expanded to evaluate bid dosing. • Aiming to launch no later than 2-3 years a
Slide 21: In EU, almost 90% of COPD treatments are BID
In EU, almost 90% of COPD treatments are BID, Spiriva® is the only OD drug 2008 Once-daily 14% More than once-daily 86% BID dosing most common Base: Adelphi Data EU (excluding France) COPD patients n= 3019 2007 Source = PRF section F1 Question: Please list ALL drugs that the patient is receiving for
Slide 22: About 65% of tiotropium prescriptions are combined with other products
About 65% of tiotropium prescriptions are combined with other respiratory products Tiotropium co-prescriptions USA EUROPE (TOP 5) 40% 40% Advair Seretide/Symbicort 35% 35% 30% 30% 25% LABAs 25% 20% 20% LABAs 15% 15% ICS 10% ICS 10% 5% ICS 5% 0% 0% TIOTROPIUM CO-PRESCRIPTIONS TIOTROPIUM CO-PRESCRIPTI
Slide 23: COPD LAMA market volume forecast
COPD LAMA market volume forecast The LAMA market is the high growth COPD market. We forecast it to grow by 14% CAGR between 2007 and 2011, reaching 33% of the COPD market by volume in 2023. Key drivers: Events impacting the broader COPD market will impact the LAMA market. As such, increasing awarene
Slide 24: COPD LAMA-LABA market volume forecast
COPD LAMA-LABA market volume forecast We forecast the LAMA-LABA market to achieve a 20% share of the total COPD market by 2023. • The LAMA-LABA market has been modelled on Spiriva plus LABA- containing product co-prescriptions, representing 39% of Spiriva prescriptions for the past few years. Source
Slide 25: Aclidinium Bromide: superior inhalation device
Aclidinium Bromide: superior inhalation device Designed for compliance with global regulatory standards (FDA, EMEA, Japan) • Inhalation device based on technology already approved in the EU. • Design modifications agreed with FDA – ongoing interactions. • Experienced group of advisors used to ensure
Slide 26: R&D newsflow
R&D newsflow Aclidinium bromide • Q1’09 – FDA meeting. • May’09 – ATS – Further details on aclidinium bromide’s Phase III data. • During 2009, start of several aclidinium bromide clinical trials will be announced. Rest of Pipeline • Q1’09 – Sativex Phase III available (Spasticity). • H1’09 – New dat
Slide 27: Mr. Eduardo Sanchiz, Chief Financial Officer
Mr. Eduardo Sanchiz Chief Financial Officer 27
Slide 28: Financial performance
Financial performance • Sales CAGR’04-07: 4,2% • Consistent sales growth over the years. • H1’07-H1’08: 13% • Substantial Normalised Net Income growth CAGR’04-07: 14% despite R&D investments to support pipeline. Cash Flow from Operating Activities > €160M in 2006/07 • Strong Cash Flow generation. an
Slide 29: Debt details
Debt details Highlights Healthy Debt positions Term: 5 years. H1’08 FY’08 Outlook No need to refinance. Nebt Debt * 231 <1 x EBITDA Combination of loan and credit line. Equity/Assets 45% * Excluding Pension plans Key takeaways Solid balance sheet with low Net Debt No need to refinance Ro
Slide 30: Summary Income Statement
Summary Income Statement CAGR % CAGR % H1'07- € MM 2004 2005 2006 2007 04-'07 H1'07 H1'08 H1'08 Net Sales 699,7 736,1 758,0 792,5 4,2% 412,9 467,9 13,3% % Change 3,5% 5,2% 3,0% 4,5% N.A. 13,3% Gross Profit 449,2 465,2 474,7 484,6 2,6% 264,7 294,7 11,3% % Margin 64,2% 63,2% 62,6% 61,1% 64,1% 63,0% Ot
Slide 31: Financial achievements vs. IPO key messages
Financial achievements vs. IPO key messages IPO message: - Stable top line evolution, excluding acquisitions - High single digit earnings evolution - Recurrent Cash Flow Generation 2006 2007 2008 Outlook € Million Low double digit Sales 758 792 growth EBITDA 144,0 170,3 + 30% Normalized Net Income 1
Slide 32: Moving forward in 2008
Moving forward in 2008 Financial guidance reiterated: H1 Results in track to meet financial targets • Group sales expected to grow at low double digit. • International Sales expected to account c. 40-45%. • Gross Margin to improve as percentage on sales. • Other Income growth by aprox. 25%. • R&D ex
Slide 33: Financial Outlook 2009
Financial Outlook 2009 A brief to financial guidance in 2009 • 2009 P&L perspectives : − Expected single digit growth in sales, EBITDA and Normalised Net Income. − R&D expense to grow at single digit. − Pay-out policy to be maintained at 35-40% • Healthy financial structure not overleveraged 33
Slide 34: Appendixes
Appendixes 34
Slide 35: Almirall - Growth, innovation and financial performance
Almirall - Growth, innovation and financial performance Corporate profile and key facts Headquarters • A growing R&D-driven pharma company listed in 2007 – Founded in 1943. Headquartered in Barcelona, Spain. c 3,400 people worldwide. – # 1 Spanish pharma, #3 in Spanish market. – Diversified, branded
Slide 36: A successful combination of R&D and business development
A successful combination of R&D and business development The Almirall business model Income From Proprietary Products (45% in 2007) Income From Other Companies Products (55% in 2007) Out-licensing Almirall Markets Quid-pro-quo (15%) In-licensing (40%) Almirall has strategic Almirall has consolidated
Slide 37: Worldwide direct presence and 2007 local sales
Worldwide direct presence and 2007 local sales Poland Switzerland Belgium • Started in 2008 • Started in 2008 • Sales: € 10 MM Mexico • Sales: € 25 MM United Kingdom & Ireland • Started in 2008 Germany • Sales: € 21 MM France • Sales: € 68 MM Spain • Sales: € 521 MM Portugal Austria • Sales: € 10 MM
Slide 38: Spanish pharma market: legislation and market trends
Spanish pharma market : legislation and market trends Applicable Law Market trends (*) • The National Heath Service (SNS) is based on the principles of universal and equal access. It gives Spanish Market (Sales 000€) access to all citizens to a co-payment or free (elderly, chronic) scheme of medicin
Slide 39: Almirall has proven its resilience…
Almirall has proven its resilience… Sales (€ MM) 800 736 758 792 700 +3.0% +4.5% 271 676 + 5.1% 215 241 632 +3.6% +7.0% 169 583 +8.4% 161 600 141 470 +24.0% 140 515 531 521 517 521 99 491 400 443 371 200 0 2000 2001 2002 2003 2004 2005 2006 2007 Spanish Sales International and unassigned Sales Astud
Slide 40: …in one of Europe's strongest branded markets
…in one of Europe’s strongest branded markets New regulatory environment provides stable outlook Spanish pharma market reacts differently to generic launches compared to other major markets Branded Pharma in Spain Prozac Example – Post Generic Share Erosion Generic penetration has been small US Spai
Slide 41: Other examples of low generic penetration in Spain
Other examples of low generic penetration in Spain Genericisation occurs at varying speed Source: IMS Health MIDAS Market Segmentation MAT December 2007 41
Slide 42: Spain: what happens when a generic gets to market
Spain : what happens when a generic gets to market Process Resilience of spanish market to Generic penetration • The approval of a generic in the Spanish market • Historically low prices vs. European average triggers the creation of an homogeneous group. (some branded products are cheaper than gener
Slide 43: Balance Sheet
Balance Sheet June 30 % Dec 31 € Thousand 2008 of BS 2007 Goodw ill 273.861 20,1% 274.258 Highlights Intangible assets 364.475 26,8% 383.448 • Increase of accounts Property, plant and equipment 175.020 12,8% 179.340 receivable, linked to the Financial assets 9.450 0,7% 6.298 Hermal, Shire’s portfoli
Slide 44: Cash Flow
Cash Flow YTD YTD € Thousand June 2008 June 2007 Profit Before Tax 97.982 112.583 Depreciation and amortisation 31.753 14.348 Change in w orking capital -27.313 -66.462 Highlights Other adjustments 17.699 -20.384 • Cash Flow from Operating Cash Flow from Operating Activities 120.121 40.085 Activitie
Slide 45: Contact details
Contact details For further information, please contact: Jordi Molina, Head of Investor Relations Ph. +34 93 291 3087 jordi.molina@almirall.com Or visit our website: www.almirall.com
Slide 46: Almirall – Solutions with you in mind
Zé . (% Almirall Solutions with you in mind